Healwell AI and WELL Health Launch Patient-Centric Clinical Trial Platform

WELLTRUST platform uses AI to match consenting patients with clinical trials, aiming to solve recruitment bottlenecks while prioritizing data privacy and patient control.

A persistent challenge in medical research is the slow and inefficient process of finding suitable participants for clinical trials. Healwell AI Inc. and WELL Health Technologies Corp. have jointly announced a new initiative aimed at directly addressing this bottleneck. Their collaborative platform, WELLTRUST™, is designed to accelerate patient recruitment while fundamentally prioritizing individual consent and data control.

Expanding a Strategic Partnership

This launch signals a deepening of the existing collaboration between the two companies. WELL Health brings an extensive clinical footprint to the table, operating a network of more than 240 clinics across Canada. Furthermore, the company’s solutions support over 43,000 healthcare providers throughout Canada and the United States.

Healwell AI contributes its proprietary DARWEN™ artificial intelligence engine. This technology has been validated for identifying patients with rare and chronic conditions. Healwell’s subsidiary, Khure Health, is noted to already be working with six of the world’s ten largest pharmaceutical companies on programs targeting rare and specialty diseases.

The "Consent-First" Operational Model

At its core, WELLTRUST integrates WELL’s clinical infrastructure with Healwell’s DARWEN™ AI. The platform is built on a "consent-first" framework, which is central to its design for scalability and regulatory compliance. This approach is structured around three key functions:

• Patient-Controlled Consent: Individuals can proactively consent to have their anonymized health data used for specific purposes, including being contacted about potential clinical trial opportunities. This consent is revocable at any time.
• AI-Powered Matching: Within the pool of consenting patients, the DARWEN™ AI system analyzes data to identify those who are the strongest potential matches for specific study criteria.
• Integrated Governance: A unified layer for data privacy and governance is intended to meet stringent Canadian regulatory requirements. This is considered essential for facilitating future partnerships with pharmaceutical sponsors and research organizations.

The explicit consent mechanism is highlighted as the critical component for building patient trust and ensuring the platform's long-term viability within the healthcare ecosystem.

Broader Commercial Context and Timeline

The WELLTRUST announcement follows recent updates from Healwell AI on its technological integration. On February 12, the company reported progress in merging the capabilities of its Khure and Pentavere units into a unified DARWEN™ engine.

Looking ahead, Healwell has outlined plans to launch "Amadeus AI" in North America in the first half of 2026, with an international expansion slated for late 2026.

The initial commercial use case for WELLTRUST is clearly defined: to more effectively identify and engage patients suffering from chronic, rare, and complex diseases for clinical research. The thesis is that by finding suitable candidates faster and in greater numbers, trials can commence and proceed more efficiently without compromising data privacy or patient rights.

Market Performance and Path Forward

Despite a minor gain on the day of the announcement, Healwell AI's shares, trading at €0.40, reflect a challenging period. The stock price has declined by 63.89% over the preceding 12 months, indicating continued high volatility.

The platform's initial rollout is now underway in WELL-operated clinics. Its ultimate success and broader commercial impact will likely depend on the speed of this deployment and its adoption as a standard process for study recruitment. The launch this week represents the first concrete step on that path.